MedTrace Logo

Tofacitinib For Treatment Of Chronic Pouchitis

NCT04580277 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-04-04

Study results available
· View outcomes & findings →

Summary

A phase 2 pilot study to evaluate the effectiveness of tofacitinib in subjects with chronic pouchitis

Conditions

  • Pouchitis
  • Ileal Pouchitis
  • Ileal Pouch

Interventions

DRUG

Tofacitinib 10 mg

Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks

Sponsors & Collaborators

  • Cedars-Sinai Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-25
Primary Completion
2022-12-01
Completion
2023-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04580277 on ClinicalTrials.gov